All news

The findings of a research study that discovered a treatment for early stage Alzheimer’s disease have been hailed as “momentous” by Alzheimer’s Research UK.  The new treatment, lecanemab, is the first drug to slow cognitive decline in people with early signs of the condition. The CLARITY-AD study enrolled 1,795 patients with early-stage Alzheimer’s globally, including Join […]

More than 60,000 people across the UK have now signed up to Join Dementia Research to be informed of dementia studies they can take part in. Since the service began in 2015, a total of 61,639 people have signed up, with 69,515 enrolments into studies during this period. Professor John O’Brien, NIHR National Specialty Lead […]

A Scottish study which recruited participants through Join Dementia Research has published their findings on the effects of the adapted dementia diagnosis and consultation processes during the COVID-19 pandemic. The research has been co-produced by the University of Edinburgh and the Better Understanding Dementia Diagnosis (BUDDs) lived experience group, and funded by UK Research and […]

A research study exploring the impact specialist anti-inflammatory drugs have on Alzheimer’s disease symptoms is looking for volunteers in London, Plymouth, Guildford and Southampton. The EXploratory PLatform trial on Anti-INflammatory agents in Alzheimer’s Disease, or EXPLAIN-AD for short, will be evaluating the effectiveness and safety of anti-inflammatory agents on common Alzheimer’s symptoms – including memory, […]

News that a potential treatment for early stage Alzheimer’s disease can slow cognitive decline is a significant development in dementia research. About the drug Lecanemab is an antibody that is designed to remove toxic beta-amyloid deposits; proteins that build up in the brains of people with Alzheimer’s disease. Following phase 3 clinical trials, pharmaceutical companies […]

Clinical trials across England and Scotland are underway to investigate if an existing diabetes medicine can potentially work as a disease-modifying option for early-stage Alzheimer’s disease. Novo Nordisk is now working alongside Join Dementia Research to investigate if the medicine, known as semaglutide, could also benefit people living with early Alzheimer’s disease. What the study […]

A national research study is investigating whether a readily available anti-sickness drug could treat dementia-related hallucinations. The Trial of Ondansetron as a Parkinson’s HAllucinations Treatment, or TOP HAT study, is recruiting volunteers across England, Scotland and Wales to evaluate whether ondansetron, an anti-sickness drug used in the NHS, could also be used for treating hallucinations […]

On 14 August 2022, the Prime Minister launched a national mission to tackle dementia in memory of the late Dame Barbara Windsor. He called for volunteers to join ‘Babs’ Army’ and sign up to Join Dementia Research. Since then we’ve welcomed hundreds of new people to the service from all over the UK. About Join […]

A pioneering international study is exploring how health promotion and self-management programmes could be used to support people with early-stage dementia and improve their health outcomes. The Self-management and HeAlth Promotion in early-stage dementia with E-learning for carers study, or SHAPE for short, is looking to recruit people with a mild to moderate dementia diagnosis […]

There are almost one million people with dementia in the UK and the most common cause is Alzheimer’s disease. Researchers from University College London (UCL) with funding from the National Institute for Health and Care Research are testing a new approach to the treatment of mild Alzheimer’s disease in the DESPIAD (DEpletion of SaP in […]